DRG Epidemiology's coverage of the HPV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of HPV vaccine for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology's HPV vaccine forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HPV vaccine over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following HPV vaccine patient populations:

Vaccine eligible population Newly eligible for vaccine population Note: coverage may vary by country and region.

Table of contents

  • Human Papilloma Virus Vaccine - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Overview
          • HPV Vaccine Eligible Adolescent Female Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adolescent Male Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adult Female Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adult Male Population per 1,000 People in 2018 and 2038
          • Relative Sizes of the Contributing Factors to the Trend in Total Eligible Female Adolescent Population for the HPV Vaccine Over the Next 20 Years
      • Epidemiology Data
      • Methods
        • HPV Vaccine Eligible Population
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of the Human Papillomavirus Vaccine
          • Studies Excluded from the Analysis of the Human Papillomavirus Vaccine
        • Risk/Protective Factors
          • Risk/Protective Factors for Human Papillomavirus Vaccine
        • Bibliography

    Author(s): Alison Isherwood, MSc, MRes, PhD

    Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.